Ascendis Pharma A/S ASND
Set alert
251.27 USD -1.73 -0.68%
At close · Oct 30
252.00 +0.73 +0.29%
After hours · Oct 30, 4:00 PM ET
249.55 Day range 255.61
196.01 52-week range 277.18
- YTD
- +17.83%
- 1 year
- +23.35%
- Open
- 253.50
- Prev close
- 253.00
- Mkt cap
- 16.53B
- Vol
- 386.70K
- Avg vol
- 704.98K
- EPS
- 13.05
- P/E
- 19.25
- Div yield
- 0.00%
More statistics
- Low
- 249.55
- High
- 255.61
- Forward P/E
- 25.06
- Beta
- 0.00
- Short ratio
- 3.27
- Inst. own
- 102.77%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 11, 2026
- 50-d avg
- 242.38
- 200-d avg
- 237.93
- 1y target
- 304.02
MAX chart
Events in this range
- Aug 7, 2025Earnings: -0.93; estimate -1.42; surprise 34.51%
- May 7, 2026Earnings: 0.32; estimate 0.1876; surprise 70.58%
- Sep 1, 2026Rating: Wedbush · Outperform → Outperform
- Sep 1, 2026Rating: Morgan Stanley · Overweight → Overweight
- Sep 2, 2026Rating: Oppenheimer · Outperform → Outperform
Signals (44)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Oct 1, 2026 | 1 month ago |
| SMA: Bearish | Sep 1, 2026 | 2 months ago |
| RSI: Overbought | Aug 1, 2026 | 3 months ago |
| RSI: Overbought | Sep 1, 2025 | 1 year ago |
| SMA: Bullish | Feb 1, 2025 | 1 year ago |
| SMA: Bearish | Oct 1, 2024 | 2 years ago |
| SMA: Bullish | Dec 1, 2023 | 2 years ago |
| SMA: Bullish | Nov 1, 2023 | 3 years ago |
| MACD: Buy Signal | Nov 1, 2023 | 3 years ago |
| MACD: Sell Signal | Apr 1, 2023 | 3 years ago |
| SMA: Bearish | Mar 1, 2023 | 3 years ago |
| MACD: Buy Signal | Dec 1, 2022 | 3 years ago |
| SMA: Bullish | Oct 1, 2022 | 4 years ago |
| SMA: Bearish | Nov 1, 2021 | 5 years ago |
| SMA: Bearish | Nov 1, 2021 | 5 years ago |
| SMA: Bullish | Aug 1, 2021 | 5 years ago |
| SMA: Bullish | Aug 1, 2021 | 5 years ago |
| SMA: Bearish | Jul 1, 2021 | 5 years ago |
| SMA: Bearish | Mar 1, 2021 | 5 years ago |
| SMA: Bullish | Feb 1, 2021 | 5 years ago |
| SMA: Bearish | Jan 1, 2021 | 5 years ago |
| MACD: Sell Signal | Jan 1, 2021 | 5 years ago |
| RSI: Overbought | Nov 1, 2020 | 6 years ago |
| SMA: Bullish | Apr 1, 2020 | 6 years ago |
| MACD: Buy Signal | Apr 1, 2020 | 6 years ago |
| SMA: Bearish | Mar 1, 2020 | 6 years ago |
| MACD: Sell Signal | Mar 1, 2020 | 6 years ago |
| RSI: Overbought | Dec 1, 2019 | 6 years ago |
| SMA: Bullish | Oct 1, 2019 | 7 years ago |
| SMA: Bearish | Sep 1, 2019 | 7 years ago |
| RSI: Overbought | Mar 1, 2019 | 7 years ago |
| SMA: Bullish | Jan 1, 2019 | 7 years ago |
| SMA: Bearish | Dec 1, 2018 | 7 years ago |
| SMA: Bullish | Nov 1, 2018 | 8 years ago |
| SMA: Bearish | Oct 1, 2018 | 8 years ago |
| RSI: Overbought | Nov 1, 2017 | 9 years ago |
| RSI: Overbought | Sep 1, 2017 | 9 years ago |
| RSI: Overbought | Apr 1, 2017 | 9 years ago |
| RSI: Overbought | Feb 1, 2017 | 9 years ago |
| SMA: Bullish | Aug 1, 2016 | 10 years ago |
| SMA: Bearish | Apr 1, 2016 | 10 years ago |
| SMA: Bullish | Mar 1, 2016 | 10 years ago |
| SMA: Bearish | Feb 1, 2016 | 10 years ago |
| SMA: Bullish | Dec 1, 2015 | 10 years ago |
Financial health
Altman Z-Score
10.33 Safe zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
6 / 9 Average
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
B3 / 5 overall
- DCF 1
- Return on Equity 5
- Return on Assets 5
- Debt / Equity 2
- P/E 3
- P/B 1
Valuation
P/E -50.1×
FY 2016 5y median -16.9× FY 2025
P/S 15.9×
FY 2016 5y median 24.0× FY 2025
P/B -67.6×
FY 2016 5y median -44.0× FY 2025
P/FCF 252×
FY 2016 5y median -13.7× FY 2025
EV/EBITDA -103×
FY 2016 5y median -17.1× FY 2025
EV/Sales 16.3×
FY 2016 5y median 25.4× FY 2025
FCF Yield 0.4%
FY 2016 5y median -6.8% FY 2025
Profitability
Gross Margin 85.1%
FY 2016 5y median 83.4% FY 2025
Operating Margin -18.9%
FY 2016 5y median -170.8% FY 2025
Net Margin -31.7%
FY 2016 5y median -180.5% FY 2025
ROE 134.6%
FY 2016 5y median 134.6% FY 2025
ROIC -18.2%
FY 2016 5y median -45.2% FY 2025
ROA -16.8%
FY 2016 5y median -35.4% FY 2025
Growth (YoY)
Revenue 90.2%
FY 2016 FY 2025
Operating Income 53.0%
FY 2016 FY 2025
EPS (diluted) 44.6%
FY 2016 FY 2025
Free Cash Flow 114.2%
FY 2016 FY 2025
Financial Health
Current Ratio 1.0×
FY 2016 5y median 1.2× FY 2025
Quick Ratio 0.8×
FY 2016 5y median 0.8× FY 2025
Debt / Equity -5.4×
FY 2016 5y median -5.1× FY 2025
Net Debt / EBITDA -2.3×
FY 2016 5y median -0.9× FY 2025
Interest Coverage -1.7×
FY 2016 5y median -10.3× FY 2025
Dividends
Dividend Yield 0.0%
FY 2016 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2016 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31